Skip to content

The Combined Effect of Mesenchymal Stem Cell, HA-CaSO4,BMP-2, and Implant in Inducing The Healing of Critical-Sized Bone Defect

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01725698
Enrollment
5
Registered
2012-11-14
Start date
2012-11-30
Completion date
2014-12-31
Last updated
2012-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Union

Brief summary

This research is aimed to evaluate the combination of mesenchymal stem cell, HA-CaSO4, BMP-2, and implant in treating critical-sized bone defect. In the presence of critical-sized bone defect whose defect size is more than 2.5 cm, bone will suffer a healing disturbance. In treating these conditions, the conventional method were vascularised bone grafting and bone transport. But the existing methods of treatment have many weaknesses Vascularized bone graft is a procedure with a high level of difficulty. Hence not every orthopaedic surgeon were able to perform it. It also takes more operating time and its failure rate is also quite high. Meanwhile, external fixation which is applied with bone transport, was being often complained by the patient in terms of cosmetic and psychologically. According to diamond concept of bone healing, there are four main factors that influence the bone healing. These factors are osteogenic factor (mesenchymal stem cell), osteconductive factor (HA-CaSO4), osteoinductive factor (bone morphogenetic protein-2) and mechanical component (implant). The potency of each component in fracture healing with/out bone defect has been proved in many studies. The combined effect of these components is often studied as well, but not in critical-sized bone defect.

Interventions

DRUGMesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
17 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* subjects with critical size defect of bone

Exclusion criteria

* subjects with patological fracture caused by primary or secondary bone malignancy, imunological deficit, active hepatitis or those who's under immunosuppresant therapy or other therapeutic modality that can interferes with bone healing.

Design outcomes

Primary

MeasureTime frameDescription
RADIOGRAPHIC UNION SCALE (RUST Score) as a measure of bone unionBefore surgery, after surgery, week 4 , 8, 12, 16, 20, 24 up to 1.5 yearsplain radiograps will be taken to determine whether the bone has healed.

Secondary

MeasureTime frameDescription
Visual analog scale as the measure of clinical unionBefore surgery, after surgery, week 4 , 8, 12, 16, 20, 24 up to 1.5 yearsWe will measure VAS (grade 0-10) to determine the clinical union

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026